• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials.

作者信息

Sattar Yasar, Alraies M Chadi

机构信息

Department of Cardiology, West Virginia University, Morgantown, West Virginia.

Department of Cardiology, Wayne State University, Detroit Medical Center, Detroit, Michigan, USA.

出版信息

Ann Med Surg (Lond). 2024 Jul 3;86(9):4941-4943. doi: 10.1097/MS9.0000000000002215. eCollection 2024 Sep.

DOI:10.1097/MS9.0000000000002215
PMID:39238993
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11374301/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d368/11374301/5775614ee900/ms9-86-4941-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d368/11374301/5775614ee900/ms9-86-4941-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d368/11374301/5775614ee900/ms9-86-4941-g001.jpg

相似文献

1
Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials.二十碳五烯酸乙酯对心血管结局及冠心病预防的作用：一项随机临床试验的荟萃分析
Ann Med Surg (Lond). 2024 Jul 3;86(9):4941-4943. doi: 10.1097/MS9.0000000000002215. eCollection 2024 Sep.
2
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.依折麦布辛伐他汀乙酯降低有既往冠状动脉旁路移植术病史患者的缺血事件发生率：RE- DUCTE-IT CABG。
Circulation. 2021 Dec 7;144(23):1845-1855. doi: 10.1161/CIRCULATIONAHA.121.056290. Epub 2021 Oct 28.
3
An Opportunity to Improve Secondary Prevention With Icosapent Ethyl in Patients Who Have Undergone Coronary Artery Bypass Graft Surgery.在接受冠状动脉旁路移植术的患者中使用二十碳五烯酸乙酯改善二级预防的机会。
Cardiovasc Revasc Med. 2022 Aug;41:170-172. doi: 10.1016/j.carrev.2021.12.025. Epub 2021 Dec 30.
4
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.依泽替米贝降低血管重建风险：REDCUATE-IT 血管重建分析结果。
Circulation. 2021 Jan 5;143(1):33-44. doi: 10.1161/CIRCULATIONAHA.120.050276. Epub 2020 Nov 5.
5
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.依泽替米贝降低严重高甘油三酯血症患者心血管风险
N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.
6
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.降低欧洲剩余心血管风险：欧洲药品管理局批准依泽替米贝/二十碳五烯酸的治疗意义。
Pharmacol Ther. 2022 Sep;237:108172. doi: 10.1016/j.pharmthera.2022.108172. Epub 2022 Mar 15.
7
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.依折麦布辛伐他汀在伴有已确诊心血管疾病或糖尿病的不同肾功能患者中的获益：REDUCE-IT RENAL 研究。
Circulation. 2021 Nov 30;144(22):1750-1759. doi: 10.1161/CIRCULATIONAHA.121.055560. Epub 2021 Oct 28.
8
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.依泽替米贝治疗经皮冠状动脉介入治疗后患者的缺血事件：来自 REDUCE-IT PCI 的见解。
J Am Heart Assoc. 2022 Mar 15;11(6):e022937. doi: 10.1161/JAHA.121.022937. Epub 2022 Mar 9.
9
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.降脂治疗在德国心血管预防中的成本效益。
Cardiovasc Drugs Ther. 2023 Aug;37(4):683-694. doi: 10.1007/s10557-021-07310-y. Epub 2022 Jan 11.
10
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.依折麦布辛伐他汀对全因缺血事件的影响：来自 REDUCE-IT 研究。
J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

引用本文的文献

1
Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis.评估ω-3疗法及其心血管益处：二十碳五烯酸乙酯情况如何？一项系统评价与荟萃分析。
Pharmaceuticals (Basel). 2025 Apr 20;18(4):601. doi: 10.3390/ph18040601.

本文引用的文献

1
RETRACTED: Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: A meta-analysis.撤回：二十碳五烯酸乙酯在糖尿病中的心血管结局：一项荟萃分析。
Ann Med Surg (Lond). 2022 Nov 17;84:104846. doi: 10.1016/j.amsu.2022.104846. eCollection 2022 Dec.
2
Correction to: Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.对以下内容的更正：美国心脏协会2022年科学会议的最新科学摘要和特色科学摘要，以及复苏科学研讨会2022年复苏科学方面的最新摘要。
Circulation. 2023 Feb 28;147(9):e649. doi: 10.1161/CIR.0000000000001138. Epub 2023 Feb 27.
3
Re: 'Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: a meta-analysis'.
关于：“二十碳五烯酸乙酯在糖尿病中的心血管结局：一项荟萃分析”。
Ann Med Surg (Lond). 2023 Jan 12;85(2):322. doi: 10.1097/MS9.0000000000000002. eCollection 2023 Feb.
4
Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease.二十碳五烯酸与二十二碳六烯酸对心血管疾病的预防作用
Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):87-93. doi: 10.1097/MED.0000000000000796. Epub 2022 Dec 23.
5
Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study.随机试验评估联合治疗在二级预防中的疗效方案和基线特征：随机对照试验和观察性生物标志物研究的组合——瑞舒伐他汀和二十碳五烯酸的二次预防效果评价研究（RESPECT-EPA）。
Am Heart J. 2023 Mar;257:1-8. doi: 10.1016/j.ahj.2022.11.008. Epub 2022 Nov 11.
6
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.2021年美国心脏病学会（ACC）关于持续性高甘油三酯血症患者降低动脉粥样硬化性心血管疾病（ASCVD）风险管理的专家共识决策路径：美国心脏病学会解决方案集监督委员会报告
J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. doi: 10.1016/j.jacc.2021.06.011. Epub 2021 Jul 28.
7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
8
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.依泽替米贝在他汀类药物治疗基础上甘油三酯升高患者中对冠状动脉粥样硬化进展的影响：EVAPORATE 试验的最终结果。
Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652.
9
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.REDCUE-IT 美国研究：3146 例美国患者随机分组结果。
Circulation. 2020 Feb 4;141(5):367-375. doi: 10.1161/CIRCULATIONAHA.119.044440. Epub 2019 Nov 11.
10
RoB 2: a revised tool for assessing risk of bias in randomised trials.《随机对照试验偏倚风险评估工具2：修订版》
BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.